drugset / Trial / NCT00505089
Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will investigate the pharmacokinetic (PK) / total IL-1beta pharmacodynamic (PD) relationship in joint fluids of patients with rheumatoid arthritis (RA) treated with different doses of ACZ885 and to evaluate the impact of the subcutaneous (s.c.) versus intravenous (i.v.) route of administration.
Timeline
- Start
- 2007-08
- Primary completion
- 2009-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | 1 mg/kg | Subcutaneous |
| Subject | Canakinumab | Monoclonal antibody | 2 mg/kg | Subcutaneous |
| Subject | Canakinumab | Monoclonal antibody | 5 mg/kg | Subcutaneous |
| Subject | Canakinumab | Monoclonal antibody | 10 mg/kg | Subcutaneous |